We'll be very selective and savvy
about which compounds to develop.

Our criteria include:
— late pre-clinical or early clinical stage
— < 3.5 years to human Proof Of Concept
— < $15M to human Proof Of Concept
— Both small and large molecules

Our experimental design will be stringent and will rapidly uncover flaws in the drug candidates.  We'll discontinue development of compounds that don't work out faster because we aren't invested in the company, we're invested in the drug candidate.  Our model allows us to reallocate funds from drug candidates that fail to drug candidates with promise, thus we profit by applying high standards and rapid development.
 

Click here to submit a drug candidate for us to review.